Boston Scientific (BSX) has been upgraded to a 'Strong Buy' rating due to its current undervaluation, trading at a forward P/E of 13.1, which is below its historical average. Despite some growth challenges in WATCHMAN and electrophysiology segments, the company benefits from strong momentum in Interventional Cardiology and Vascular Therapies. The recent acquisition of Penumbra and the IVL product line position BSX for renewed growth, supported by a solid balance sheet and favorable industry trends. This creates an attractive entry point for long-term investors seeking defensive stocks with growth potential.
Boston Scientific (BSX) is currently trading at USD 45.04, just above its 52-week low of USD 42.63, and well below its 52-week high of USD 104.98 as of Sep 15, 2026 18:13 WIB. This price level highlights the deep discount referenced in the upgrade, despite the company's strong market cap of $65.29 billion. The stock's minimal 1-day change of -0.02% shows relative stability at this lower valuation point.
